vimarsana.com

Page 59 - ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Firm seeks DCGI nod to extend Covaxin shelf life even as high prices raise eyebrows

Firm seeks DCGI nod to extend Covaxin shelf life even as high prices raise eyebrows
nationalheraldindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationalheraldindia.com Daily Mail and Mail on Sunday newspapers.

covaxin: Bharat Biotech seeks DCGI s nod to extend shelf life of Covaxin

Synopsis The Hyderabad-based Bharat Biotech was given permission for sale and distribution of Covaxin with shelf life of six months when stored at two to eight degrees Celsius. In support of their proposal, Bharat Biotech has submitted updated accelerated and real-time stability data of Coaxin along with the justification for the extension of shelf-life. AFP Bharat Biotech has written to the India s drug regulator seeking extension of the shelf-life of its indigenously developed COVID-19 vaccine Covaxin from six to 24 months, sources said on Sunday. Covaxin, along with Covishield manufactured by Serum Institute of India, are the two vaccines so far being used in India s current COVID-19 vaccination drive. Russian vaccine Sputnik-V has also been approved for emergency use in India.

Covaxin at Rs 1,200 per dose for private hospitals, call for Centre funds

Search Home / India / Covaxin at Rs 1,200 per dose for private hospitals, call for Centre funds Covaxin at Rs 1,200 per dose for private hospitals, call for Centre funds It is twice the corresponding price tag on Covishield, the AstraZeneca vaccine produced in the country by the Serum Institute of India Covaxin, India’s home-grown Covid-19 vaccine from Bharat Biotech, will cost Rs 1,200 per dose for private hospitals, twice the corresponding price tag on Covishield, the AstraZeneca vaccine produced in the country by the Serum Institute of India. The price has been announced in the middle of an uproar over the Centre’s hands-off policy that has passed the vaccine buck to the states and citizens. On Saturday, Arvind Subramanian, the chief economic adviser to the Union government during Narendra Modi’s first innings, made it clear t

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.